Enclomiphene Citrate for Secondary Hypogonadism: Evidence, Dosing, and What to Expect

What Is Secondary Hypogonadism and Why Does the Diagnosis Matter?

Secondary hypogonadism is a hormonal disorder in which testosterone production falls because the signal chain from the brain to the testes breaks down, not because the testes themselves are damaged. The hypothalamus fails to secrete adequate gonadotropin-releasing hormone (GnRH), the pituitary responds with low or inappropriately normal LH and FSH, and the Leydig cells of the testes receive too little stimulation to produce adequate testosterone. Because the testes retain their functional capacity, this diagnosis opens the door to treatments that work upstream rather than replacing testosterone directly.

The American Urological Association defines male hypogonadism as a total serum testosterone consistently below 300 ng/dL on two separate morning samples, with symptoms of androgen deficiency [1]. Secondary hypogonadism specifically adds the finding of LH below 8 mIU/mL, confirming the pituitary-hypothalamic origin rather than primary testicular failure. This distinction is not academic. A man with secondary hypogonadism who starts exogenous testosterone will almost always see his LH and FSH fall further toward zero, suppressing spermatogenesis and shrinking testicular volume, sometimes irreversibly after years of use [2].

Common underlying causes include obesity, type 2 diabetes, sleep apnea, hyperprolactinemia, chronic opioid use, pituitary adenoma, and idiopathic hypothalamic suppression. A thorough workup should include prolactin, TSH, morning cortisol, MRI of the pituitary if LH is below 2 mIU/mL, and a semen analysis if fertility is a concern [3]. Identifying and treating the root cause remains the first clinical step. For the residual hormonal deficit that persists even after lifestyle modification, enclomiphene citrate offers a targeted pharmacological option.

How Enclomiphene Citrate Works: The Mechanism in Plain Terms

Enclomiphene restores testosterone by blocking estrogen receptors at the level of the hypothalamus and pituitary, which removes the negative feedback that estrogen normally exerts on GnRH and gonadotropin secretion. The result is a measurable rise in LH and FSH, followed by increased intratesticular testosterone synthesis within days to weeks [4].

Clomiphene citrate, the parent compound used for decades in female infertility, is a 50/50 mixture of two stereoisomers: enclomiphene (the trans-isomer) and zuclomiphene (the cis-isomer). Enclomiphene is the pharmacologically active estrogen antagonist responsible for the gonadotropin-stimulating effect. Zuclomiphene, by contrast, is a weak estrogen agonist with a very long half-life, approximately 30 days, and accumulates in tissue with repeated dosing. In men, accumulated zuclomiphene may contribute to mood disturbance and visual symptoms reported with long-term clomiphene use [5].

By isolating the enclomiphene isomer, the pharmaceutical goal was to preserve the testosterone-raising benefit while reducing the estrogenic side effects tied to zuclomiphene accumulation. This pharmacological rationale is supported by the mechanistic work reviewed by Wiehle et al. (2013), who demonstrated that enclomiphene as a single isomer produced LH and FSH elevations comparable to racemic clomiphene but with a cleaner hormonal profile in healthy male volunteers [6].

The clinical net effect: a man's own Leydig cells produce more testosterone, his testes remain active, and his sperm count is maintained or may even improve. This stands in direct contrast to exogenous testosterone replacement, where the pituitary detects supraphysiologic androgen levels and shuts down gonadotropin release almost immediately [2].

Clinical Trial Evidence: What the Data Actually Show

The single most cited study for enclomiphene in secondary hypogonadism is Kim et al., published in BJU International in 2016 (PMID 26614366) [7]. The study enrolled men with secondary hypogonadism, defined as total T below 300 ng/dL with LH below 8 mIU/mL, and treated them with enclomiphene citrate at doses of 12.5 mg or 25 mg daily. After 3 months of treatment, serum testosterone levels rose significantly in both dose groups, with the 25 mg group reaching mean testosterone levels above 400 ng/dL. Critically, LH and FSH remained elevated throughout treatment, and spermatogenesis was not suppressed. The authors concluded that enclomiphene "represents an effective, orally administered treatment for secondary hypogonadism that preserves the pituitary-gonadal axis" [7].

Wiehle et al. published two controlled studies in Andrologia (2014) and the International Journal of Andrology (2013) examining enclomiphene versus placebo and versus testosterone gel in men with secondary hypogonadism. In the comparison with testosterone gel (AndroGel 1.62%), enclomiphene 12.5 mg and 25 mg produced testosterone normalization rates statistically non-inferior to testosterone gel at 16 weeks, while testosterone gel produced the expected suppression of LH (from baseline means near 4.8 mIU/mL down to below 1 mIU/mL) [6]. Enclomiphene-treated men maintained LH above 4 mIU/mL throughout.

A pooled analysis across three Repros Therapeutics-sponsored phase II and phase III trials (combined N approximately 600) showed that 12.5 mg enclomiphene normalized testosterone in roughly 60% of men with secondary hypogonadism at 12 weeks, and 25 mg normalized testosterone in approximately 75% [8]. The FDA reviewed these data during the New Drug Application process for Androxal (the brand-name enclomiphene citrate). The agency ultimately did not approve Androxal for hypogonadism in 2013, citing concerns about the sufficiency of long-term cardiovascular and safety data rather than doubts about efficacy [9]. The drug was approved only for inducing ovulation in anovulatory women under a different indication pathway.

That regulatory history explains why enclomiphene remains off-label for men, despite a reasonably substantial evidence base supporting its biological rationale and short-term efficacy [9].

Enclomiphene vs. Testosterone Replacement Therapy: A Clinical Comparison

The choice between enclomiphene and TRT is not a matter of one being superior overall. It depends on the patient's priorities, specifically around fertility, convenience, long-term monitoring burden, and symptom timeline.

Exogenous testosterone (injectable testosterone cypionate, topical gels, subcutaneous pellets) produces faster symptomatic relief in most men. A patient starting weekly testosterone cypionate injections at 100-200 mg typically sees total testosterone normalization within two to three weeks and reports symptomatic improvement in libido, energy, and mood within four to six weeks. The tradeoff: LH and FSH drop toward zero, intratesticular testosterone falls sharply, testicular volume decreases by 10-25% over 6-12 months, and azoospermia is common after 12-18 months of continuous use [2].

Enclomiphene works more slowly. Most men do not feel meaningful symptomatic improvement until weeks six to ten, because the hormonal response is indirect. The testes need time to upregulate steroidogenesis in response to rising LH. Some men require the full 12 weeks before reporting consistent improvement in energy and libido.

The fertility preservation argument is categorical, not a matter of degree. Men who want biological children within the next two to five years, or who are unwilling to risk long-term fertility suppression, should not start exogenous TRT without a frank discussion of that tradeoff. For those men, enclomiphene or hCG-based protocols are the standard-of-care alternatives recommended by the American Urological Association and the American Society for Reproductive Medicine [10].

The HealthRX clinical team uses the following decision framework for men presenting with secondary hypogonadism (total T <300 ng/dL, LH <8 mIU/mL):

Tier 1: Treat reversible causes first. Weight loss of 10% body weight in obese men can raise testosterone by 60-100 ng/dL. Treat sleep apnea, discontinue offending medications, normalize prolactin if elevated.

Tier 2: If testosterone remains below 300 ng/dL after 3-6 months of lifestyle intervention and the patient desires preserved fertility, offer enclomiphene citrate 12.5 mg daily with re-evaluation at 8 weeks.

Tier 3: If fertility is not a concern and the patient has not responded to enclomiphene after 16 weeks at 25 mg daily, discuss transition to testosterone cypionate or testosterone enanthate with appropriate monitoring.

Tier 4: If the patient later wants to attempt conception while on TRT, a restart protocol using hCG (500-1000 IU every other day) plus enclomiphene may be necessary to recover spermatogenesis, typically over 6-18 months.

Dosing Protocol for Secondary Hypogonadism

Starting dose is 12.5 mg orally once daily, taken at the same time each day with or without food. The dose can be increased to 25 mg once daily if total testosterone remains below 350 ng/dL at the 4-to-8-week follow-up visit and the patient is tolerating the lower dose without significant side effects [7].

Some compounding pharmacies prepare enclomiphene in 6.25 mg increments, which allows a more gradual titration for men who are sensitive to estrogen-related side effects or who start with total T levels in the 200-250 ng/dL range and need a cautious approach. A slower titration schedule is also reasonable for men over 50, whose baseline estradiol levels may already be on the higher end of normal.

Monitoring labs should be drawn at baseline and repeated at 4-8 weeks. The minimum panel includes: total testosterone (morning sample, 8-10 AM), LH, FSH, estradiol (sensitive assay), CBC, and a comprehensive metabolic panel. An estradiol level above 42 pg/mL in the context of bothersome symptoms (gynecomastia, water retention, mood instability) may warrant a low-dose aromatase inhibitor such as anastrozole 0.25-0.5 mg twice weekly, though adding an AI to enclomiphene requires careful monitoring to avoid excessively suppressing estradiol [3].

No established maximum duration exists for enclomiphene use in men, partly because long-term controlled trial data extend only to 6 months in the published literature. Many prescribers continue treatment for 12-24 months while monitoring labs every 3-6 months. If testosterone normalizes and the patient becomes asymptomatic, an annual drug holiday of 4-8 weeks can clarify whether the underlying hypothalamic-pituitary function has recovered spontaneously, which does occur in a subset of men whose secondary hypogonadism was driven by correctable causes.

Who Qualifies: Diagnostic Criteria and Patient Selection

To prescribe enclomiphene for secondary hypogonadism responsibly, three diagnostic conditions should be met. Total testosterone must be below 300 ng/dL on two separate morning measurements. LH must be below 8 mIU/mL, confirming the central (non-testicular) origin of the deficit. And the patient must have at least two of the symptomatic criteria for hypogonadism: reduced libido, erectile dysfunction, depressed mood, fatigue, decreased muscle mass, or increased body fat [1].

Men with primary hypogonadism (elevated LH, damaged or absent testes) are not candidates. Enclomiphene stimulates LH and FSH, but if the testes cannot respond, the drug produces only elevated gonadotropins with no testosterone benefit. Similarly, men with constitutional delay of puberty require a different approach.

Men over 65 represent a gray zone. Age-related decline in testosterone, sometimes called late-onset hypogonadism, often involves both central and peripheral components. LH may be modestly elevated rather than low, making enclomiphene a poor fit mechanistically. A thorough evaluation including LH, FSH, and sex hormone-binding globulin (SHBG) is necessary before prescribing in this age group [1].

Absolute contraindications include hepatic impairment (enclomiphene is extensively hepatically metabolized), known hypersensitivity to clomiphene-class compounds, active or recent thromboembolic disease, and hypercalcemia. Relative contraindications include a history of visual disturbances on clomiphene, elevated baseline estradiol above 55 pg/mL, and untreated or poorly controlled bipolar disorder, where the mood effects of changing sex hormones may be unpredictable.

Side Effects: What Secondary Hypogonadism Patients Should Know

Enclomiphene's side effect profile in men is generally mild compared to exogenous testosterone, but patients should enter treatment with accurate expectations.

The most commonly reported side effects in the Wiehle et al. trials were headache (approximately 10% of participants), mood changes (approximately 8%), and nausea (approximately 6%) [6]. These were predominantly mild and resolved within the first four weeks for most men.

Elevated estradiol is the side effect with the most clinical consequences. As LH rises and testosterone production increases, aromatase activity in adipose tissue converts a portion of that testosterone to estradiol. Men with higher body fat percentages, particularly those with BMI above 30, are at greater risk of developing estradiol above the 42 pg/mL threshold. Symptomatic high estradiol manifests as breast tenderness, nipple sensitivity, water retention, and, in some men, emotional lability [4]. A baseline and follow-up estradiol measurement (using the sensitive LC-MS/MS assay, not the standard immunoassay) allows early detection.

Visual disturbances, including blurring and light sensitivity, occurred in a small subset of clomiphene users in older literature. These have been reported less frequently with isolated enclomiphene, likely because the zuclomiphene accumulation responsible for most visual complaints is absent. Any new visual symptom should prompt immediate discontinuation and ophthalmologic evaluation.

Thromboembolism is a class concern with SERMs. Tamoxifen and raloxifene carry FDA black box warnings for thromboembolic events in women. The absolute risk in men on enclomiphene at the doses used for hypogonadism appears low based on available trial data, but men with prior DVT, PE, or known thrombophilia should not use this drug without a hematology consultation [5].

Accessing Enclomiphene: Prescriptions, Compounding, and Regulatory Reality

Androxal, the branded pharmaceutical-grade enclomiphene citrate product developed by Repros Therapeutics, was never approved for male hypogonadism and is not currently commercially available as an FDA-approved drug in the United States for this indication [9]. What is available through legitimate channels is compounded enclomiphene citrate, prepared by 503A compounding pharmacies from API (active pharmaceutical ingredient) and dispensed with a valid physician prescription.

The quality of compounded medications varies by pharmacy. Men pursuing this treatment should confirm their pharmacy holds PCAB accreditation (Pharmacy Compounding Accreditation Board) or has passed third-party potency and purity testing. A 2023 analysis of compounded testosterone products found potency deviations of up to 30% from labeled concentration at non-accredited pharmacies, a comparable concern for compounded SERMs [11].

Telehealth prescribers, including HealthRX-affiliated physicians, can prescribe compounded enclomiphene citrate after completing a full intake evaluation, reviewing qualifying lab work, and confirming the absence of contraindications. A prescription without documented labs meeting the diagnostic criteria for secondary hypogonadism is not appropriate practice.

Insurance coverage is almost uniformly unavailable. Because the indication is off-label and no FDA-approved product exists for male hypogonadism, most major payers (Medicare, Medicaid, and commercial plans) deny coverage. Out-of-pocket costs at compounding pharmacies range from approximately $80 to $200 per month depending on dose and pharmacy. Some men find racemic clomiphene citrate (off-label, generic, FDA-approved for female infertility) less expensive at roughly $30-$60 per month; the evidence base for clomiphene in men is also more extensive, though it includes the zuclomiphene-related side effect burden described above.

Monitoring and Long-Term Management

A structured monitoring plan matters more for enclomiphene than for many other off-label prescriptions because the drug's effects on the hypothalamic-pituitary-gonadal axis are active and ongoing. Lab drift in either direction, testosterone rising too high or estradiol becoming problematic, requires dose adjustment.

The following monitoring schedule reflects the approach used by HealthRX-affiliated physicians and is consistent with AUA guideline principles for male hypogonadism management [1]:

Baseline (before first dose): Total T (AM), LH, FSH, estradiol (sensitive), prolactin, TSH, CBC, CMP, PSA (men over 40), and semen analysis if fertility is a concern.

Week 4-8: Total T (AM), LH, FSH, estradiol. Assess symptom response using a standardized tool such as the ADAM questionnaire or the Aging Males' Symptoms (AMS) scale.

Week 12-16: Full repeat of baseline panel. Dose adjustment decision made at this visit. If testosterone is above 700 ng/dL and estradiol is climbing, reduce dose to 6.25 mg daily or consider a brief drug holiday.

Every 6 months thereafter: Total T, LH, FSH, estradiol, PSA (men over 40), CBC.

Men who achieve normalized testosterone and symptom resolution by month 3-4 and want to assess the durability of their response may try a structured 8-week drug holiday at the 12-18 month mark. If testosterone remains above 300 ng/dL off drug, the hypothalamic-pituitary axis may have recovered sufficiently to sustain function independently, particularly in men who have also made meaningful lifestyle changes.